Prognostic and predictive factors in patients with metastatic gastric cancer treated with immune checkpoint inhibitors

Introduction. Microsatellite instability, PD-L1 CPS expression, high tumor mutational burden (TMB), and the presence of Epstein-Barr virus are the main tumor predictors of the response to immunotherapy in patients with metastatic gastric cancer (mGC). However, selecting patients for immunotherapy in mGC seems challenging due the lack of an optimal cut-off for PD-L1 CPS expression in microsatellite-stable gastric adenocarcinomas, significant benefit from anti-PD-L1 inhibitors in late-line treatment, and inaccessibility of Epstein-Barr virus and TMB determination in real clinical practice.

Aim. The aim of our study is to determine prognostic and predictive biomarkers of patients, who received ICIs for mGC.

Materials and methods. Our study included patients with mGC treated with anti-PD1 antibodies between 2018 and 2023 in five oncology centers in Moscow. Variables with p <0.05 obtained from a univariate analysis, were selected to perform multivariate analysis. According to the number of prognostic factors, patients were stratified into two groups with favorable and unfavorable prognosis. The optimal cut-off of the neutrophil-lymphocyte ratio (NLR) to predict of the efficacy of immunotherapy was determined using ROC analysis. The Kaplan–Meier method was performed to analyze survival curves of patients according to prognostic groups and NLR levels and the log-rank-test was used to compare the differences. Statistics was performed using the IBM SPSS v. 22 and PRISM 10.

Results. Between January 1, 2018 and February 28, 2023, 122 patients with mGC who received ICIs were included. NLR was analyzed in 71 (58 %) patients out of 122. The median NLR was 2.36 (0.41–10.00). The cut-off of NLR for predicting mortality was 1.8 (AUC 0.81, p <0.001). The median of PFS and OS in patients with high NLR (NLR ≥1.8) were 2 and 4 months, respectively; mOS and mPFS in the low NLR group were not achieved (p <0.001). Eight factors were statistically significant in univariate analysis of patients with MSS: ECOG status (0–1 and 2–3), signet-ring cell histology, primary tumor, the number of organs with metastases (1–2 and 3 or more), ascites, pain, the line of immunotherapy (I–II and III–IV) and N LR level. Multivariate analyses revealed the presence of ascites (p = 0.001), immunotherapy administration in III– IV lines (p = 0.02), and NLR≥1.8 (p = 0.004) were independent prognostic factors for OS. Each factor was assigned with a score from 1 to 2, depending on its significance: presence of ascites – 2 points, high NLR – 2 points, III–IV line of immunotherapy – 1 point. Patients were stratified into two prognostic groups according to the number of prognostic factors – the group with favorable prognosis (0–2 points, n = 20) and unfavorable prognosis (3–5 points, n = 22). The mOS of patients with favorable and unfavorable prognosis was 6 months and 3 months, respectively (p = 0.048).

Conclusion. Ascites, NLR level of ≥1.8 and administration of ICIs in late setting are associated with low efficacy of immunotherapy in patients with MSS mGC. Further research should be planned including more patients and those who did not receive ICIs to determine the prognostic significance of our model.

1. Клинические рекомендации «Рак желудка». Министерство здравоохранения Российской Федерации. 2020. https://oncology-association.ru/wp-content/uploads/2020/09/rak_zheludka.pdf

2. Chao J., Fuchs C.S., Shitara K. et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability – High gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol 2021;7(6):895–902. DOI: 10.1001/JAMAONCOL.2021.0275

3. Ignatova E.O., Seryak D.A., Fedyanin M.Y. et al. Molecular portrait of stomach cancer associated with the Epstein–Barr virus. Uspehi molekularnoj onkologii = Advances in Molecular Oncology 2020;7(3):27–36. DOI: 10.17650/2313-805X-2020-7-3-27-36

4. Liu Y., Sethi N.S., Hinoue T. et al. Comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell 2018;33(4): 721–35.e8. DOI: 10.1016/J.CCELL.2018.03.010

5. Bai Y., Xie T., Wang Z. et al. Original research: Efficacy and predictive biomarkers of immunotherapy in Epstein–Barr virus-associated gastric cancer. J Immunother Cancer 2022;10(3):4080. DOI: 10.1136/JITC-2021-004080

6. Strickler J.H., Hanks B.A., Khasraw M. Tumor mutational burden as a predictor of immunotherapy response: Is more always better? Clin Cancer Res 2021;27(5):1236–41. DOI: 10.1158/1078-0432.CCR-20-3054

7. Jang J.Y., Jeong S.Y., Kim S.T. Tumor mutational burden as a potential predictive marker for the efficacy of immunotherapy in advanced gastric cancer. J Clin Oncol 2023;41(4_suppl):324. DOI: 10.1200/JCO.2023.41.4_SUPPL.324

8. Kim Y.Y., Lee J., Jeong W.K. et al. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer 2021;24(2): 457–66. DOI: 10.1007/S10120-020-01124-X/TABLES/4

9. Sano A., Sohda M., Nakazawa N. et al. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. BMC Cancer 2022;22(1):1–12. DOI: 10.1186/S12885-021-09118-3/TABLES/7

10. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011;144(5):646–74. DOI: 10.1016/J.CELL.2011.02.013/ATTACHMENT/68024D79-3A9C-46C4-930B-640934F11E2E/MMC1.PDF

11. Ozveren A., Erdogan A.P., Ekinci F. The inflammatory prognostic index as a potential predictor of prognosis in metastatic gastric cancer. Sci Rep 2023;13(1):1–7. DOI: 10.1038/s41598-023-34778-5

12. Zhan H., Ma J.Y., Jian Q.C. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis. Clin Chim Acta 2018;484:136–40. DOI: 10.1016/J.CCA.2018.05.055

13. Vitorino M., Tomas T., Almeida S., Silva M. 176P Neutrophil-tolymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC). J Thor Oncol 2021;16(4):S793–4. DOI: 10.1016/s1556-0864(21)02018-9

14. Bayraktaroglu M., Yildiz B.P. Prognostic significance of neutrophilto-lymphocyte ratio and platelet-to-lymphocyte ratio in non-small cell lung cancer. Medicine 2023;102(26):E34180. DOI: 10.1097/MD.0000000000034180

15. Diem S., Schmid S., Krapf M. et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017;111:176–81. DOI: 10.1016/J.LUNGCAN.2017.07.024

16. Rugambwa T.K., Abdihamid O., Zhang X. et al. Neutrophil– lymphocyte ratio and platelet–lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and metaanalysis. Front Oncol 2023;13:1181248. DOI: 10.3389/FONC.2023.1181248/FULL

17. Matsas S., Aguiar Junior P.N., Del Giglio A. Prognostic role of platelet-to-lymphocyte ratio (PLR) and neutrophil-tolymphocyte ratio (NLR) in advanced gastric cancer treated with immunotherapy: A systematic review and meta-analysis. J Gastrointest Oncol 2024;42(3 suppl):397. DOI: 10.1200/JCO.2024.42.3_SUPPL.397

18. Kanagavel D., Pokataev I.A., Fedyanin M.Y. et al. A prognostic model in patients treated for metastatic gastric cancer with secondline chemotherapy. Annals of Oncol 2010;21(9):1779–85. DOI: 10.1093/annonc/mdq032

19. Shimozaki K., Nakayama I., Takahari D. et al. A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care. ESMO Open 2021;6(5):100234. DOI: 10.1016/J.ESMOOP.2021.100234

20. Schlintl V., Huemer F., Rinnerthaler G. et al. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort. BMC Cancer 2022;22(1):1–10. DOI: 10.1186/S12885-021-09115-6/FIGURES/3

21. Takahashi Y., Sunakawa Y., Inoue E. et al. Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08). Gastric Cancer 2022;25(1):235–44. DOI: 10.1007/S10120-021-01237-X/TABLES/5

22. Rays A.B., Fedyanin М.Yu., Popov D.V. et al. Efficacy of immunotherapy in advanced gastric cancer: preliminary results of a multicenter observational study. Malignant tumours 2024;14(2). DOI: 10.18027/2224-5057-2024-006

23. Karalis J.D., Ju M.R., Feig R. et al. Intensifying supportive care is associated with improved survival in gastric cancer patients with malignant ascites. J Surg Oncol 2024;129(4):718–27. DOI: 10.1002/JSO.27556

24. Donnenberg A.D., Luketich J.D., Dhupar R., Donnenberg V.S. Treatment of malignant pleural effusions: the case for localized immunotherapy. J Immunother Cancer 2019;7(1):110. DOI: 10.1186/S40425-019-0590-4

25. Fucà G., Cohen R., Lonardi S. et al. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer 2022;10(2):e004001. DOI: 10.1136/JITC-2021-004001

26. Miyamoto R., Inagawa S., Sano N. et al. The neutrophil-tolymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients. Eur J Surg Oncol 2018;44(5):607–12. DOI: 10.1016/J.EJSO.2018.02.003

27. Magdy M., Hussein T., Ezzat A., Gaballah A. Pre-treatment peripheral neutrophil-lymphocyte ratio as a prognostic marker in gastric cancer. J Gastrointest Cancer 2019;50(4):763–8. DOI: 10.1007/S12029-018-0144-X

28. Gou M., Qu T., Wang Z. et al. Neutrophil-to-Lymphocyte Ratio (NLR) predicts PD-1 inhibitor survival in patients with metastatic gastric cancer. J Immunol Res 2021;2021:2549295. DOI: 10.1155/2021/2549295

29. Cho I.R., Park J.C., Park C.H. et al. Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer 2014;17(4):703–10. DOI: 10.1007/S10120-013-0330-2

30. Kanagavel D., Fedyanin M., Tryakin A., Tjulandin S. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol 2015;21(41):11621. DOI: 10.3748/WJG.V21.I41.11621